title: Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?
abstract: Changes in the receptor binding characteristics of human H3N2 viruses have been evident from changes in the agglutination of different red blood cells (RBCs) and the reduced growth capacity of recently isolated viruses, particularly in embryonated eggs. An additional peculiarity of viruses circulating in 2005 to 2009 has been the poor inhibition of hemagglutination by postinfection ferret antisera for many viruses isolated in MDCK cells, including homologous reference viruses. This was shown not to be due to an antigenic change in hemagglutinin (HA) but was shown to be the result of a mutation in aspartic acid 151 of neuraminidase (NA) to glycine, asparagine, or alanine, which caused an oseltamivir-sensitive agglutination of RBCs. The D151G substitution was shown to cause a change in the specificity of NA such that it acquired the capacity to bind receptors, which were refractory to enzymatic cleavage, without altering its ability to remove receptors for HA. Thus, the inhibition of NA-dependent agglutination by the inclusion of oseltamivir carboxylate in the assay was effective in restoring the anti-HA specificity of the hemagglutination inhibition (HI) assay for monitoring antigenic changes in HA. Since the NA-dependent binding activity did not affect virus neutralization, and virus populations in clinical specimens possessed, at most, low levels of the "151 mutant," the biological significance of this feature of NA in, for example, immune evasion is unclear. It is apparent, however, that an important role of aspartic acid 151 in the activity of NA may be to restrict the specificity of the NA interaction and its receptor-destroying activity to complement that of HA receptor binding.
authors.affiliation: Virology Division, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom. lyipu@nimr.mrc.ac.uk
authors.forename: Yi Pu
authors.initials: YP
authors.lastname: Lin
authors.forename: Victoria
authors.initials: V
authors.lastname: Gregory
authors.forename: Patrick
authors.initials: P
authors.lastname: Collins
authors.forename: Johannes
authors.initials: J
authors.lastname: Kloess
authors.forename: Stephen
authors.initials: S
authors.lastname: Wharton
authors.forename: Nicholas
authors.initials: N
authors.lastname: Cattle
authors.forename: Angie
authors.initials: A
authors.lastname: Lackenby
authors.forename: Rodney
authors.initials: R
authors.lastname: Daniels
authors.forename: Alan
authors.initials: A
authors.lastname: Hay
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism; D001224:Aspartic Acid / Q000235:genetics*; D020134:Catalytic Domain; D002460:Cell Line; D004285:Dogs; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D007251:Influenza, Human / Q000821:virology; D020125:Mutation, Missense; D009439:Neuraminidase / Q000235:genetics* / Q000378:metabolism*; D009500:Neutralization Tests; D053139:Oseltamivir / Q000378:metabolism; D011485:Protein Binding; D011991:Receptors, Virus / Q000378:metabolism*; D014764:Viral Proteins / Q000235:genetics* / Q000378:metabolism*; D053585:Virus Attachment
chemical_list: D000998:Antiviral Agents; D011991:Receptors, Virus; D014764:Viral Proteins; D053139:Oseltamivir; D001224:Aspartic Acid; C487630:NA protein, influenza A virus; D009439:Neuraminidase
references.citation: Virology. 1984 Sep;137(2):314-23
references.pmid: 6485252
references.citation: Virology. 1991 Aug;183(2):496-504
references.pmid: 1853557
references.citation: Eur J Biochem. 1992 Jul 1;207(1):335-43
references.pmid: 1628657
references.citation: J Virol. 2005 Jun;79(11):6763-71
references.pmid: 15890915
references.citation: Antimicrob Agents Chemother. 2003 Jul;47(7):2264-72
references.pmid: 12821478
references.citation: Proteins. 1992 Nov;14(3):327-32
references.pmid: 1438172
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92
references.pmid: 18625765
references.citation: Nature. 2006 Sep 7;443(7107):45-9
references.pmid: 16915235
references.citation: Virol J. 2006 Aug 31;3:63
references.pmid: 16945126
references.citation: Virology. 2001 Oct 10;289(1):74-85
references.pmid: 11601919
references.citation: Vaccine. 2010 Feb 3;28(5):1156-67
references.pmid: 20004635
references.citation: Arch Virol. 2009;154(6):945-57
references.pmid: 19458903
references.citation: J Virol. 1986 Feb;57(2):623-8
references.pmid: 2418215
references.citation: Nature. 2008 Jun 26;453(7199):1258-61
references.pmid: 18480754
references.citation: Biochemistry. 1994 Jul 12;33(27):8172-9
references.pmid: 8031750
references.citation: J Virol. 2009 Oct;83(20):10366-73
references.pmid: 19641000
references.citation: J Virol. 1995 Feb;69(2):1099-106
references.pmid: 7815489
references.citation: Wkly Epidemiol Rec. 2009 Oct 9;84(41):421-31
references.pmid: 19817019
references.citation: Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
references.pmid: 10801978
references.citation: Antiviral Res. 2010 Feb;85(2):381-8
references.pmid: 19917319
references.citation: EMBO J. 1987 May;6(5):1459-65
references.pmid: 3608984
references.citation: J Virol. 1989 Mar;63(3):1239-46
references.pmid: 2915381
references.citation: J Infect Dis. 1979 Dec;140(6):844-50
references.pmid: 396336
references.citation: Virology. 2005 Aug 15;339(1):12-20
references.pmid: 15950996
references.citation: Nature. 1983 May 5-11;303(5912):41-4
references.pmid: 6188957
references.citation: Proteins. 1989;6(4):341-56
references.pmid: 2482974
references.citation: Science. 2009 Oct 30;326(5953):734-6
references.pmid: 19900932
references.citation: Virology. 1974 Oct;61(2):397-410
references.pmid: 4472498
references.citation: Virology. 1984 Oct 15;138(1):174-7
references.pmid: 6208680
references.citation: Virus Res. 2004 Jul;103(1-2):47-52
references.pmid: 15163487
references.citation: Virol J. 2007 May 09;4:42
references.pmid: 17490484
references.citation: Virology. 2003 Sep 1;313(2):473-80
references.pmid: 12954214
references.citation: Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12
references.pmid: 9342319
references.citation: J Virol. 1997 Sep;71(9):6706-13
references.pmid: 9261394
references.citation: Rev Med Virol. 2002 May-Jun;12(3):159-66
references.pmid: 11987141
references.citation: Virology. 2000 Dec 20;278(2):587-96
references.pmid: 11118381
references.citation: J Virol. 1987 Sep;61(9):2910-6
references.pmid: 3612957
references.citation: J Virol. 2000 Jul;74(13):6015-20
references.pmid: 10846083
references.citation: J Virol. 2004 Nov;78(22):12665-7
references.pmid: 15507653
references.citation: J Virol. 2003 Aug;77(15):8418-25
references.pmid: 12857911
references.citation: Virology. 1998 Feb 1;241(1):101-11
references.pmid: 9454721
references.citation: Annu Rev Biochem. 2000;69:531-69
references.pmid: 10966468
references.citation: Eur J Biochem. 1998 Dec 1;258(2):320-31
references.pmid: 9874196
references.citation: Nat Struct Biol. 1999 Jun;6(6):530-4
references.pmid: 10360354